Paper42477293
CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.
Ellyan NS and 4 others. Clin Exp Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies. Papers, record 42477293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42477293
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Triple Negative Breast Neoplasms | Major topic |
| Casein Kinase II | Major topic |
| Signal Transduction | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Female | |
| Animals | |
| Epithelial-Mesenchymal Transition |
Source PubMed
References122
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31443516 | Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. | Cells | 2019 | https://conductscience.org/library/papers/31443516 | PubMed |
| 2 | 32218358 | Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors. | Molecules | 2020 | https://conductscience.org/library/papers/32218358 | PubMed |
| 3 | 15818404 | Protein kinase CK2 phosphorylates and upregulates Akt/PKB. | Cell Death Differ | 2005 | https://conductscience.org/library/papers/15818404 | PubMed |
| 4 | 32088086 | Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets. | Pathol Res Pract | 2020 | https://conductscience.org/library/papers/32088086 | PubMed |
| 5 | 22317921 | Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. | Sci Signal | 2012 | https://conductscience.org/library/papers/22317921 | PubMed |
| 6 | 25916826 | SHP2: a new target for pro-senescence cancer therapies. | EMBO J | 2015 | https://conductscience.org/library/papers/25916826 | PubMed |
| 7 | 24051329 | Requirement of B-Raf, C-Raf, and A-Raf for the growth and survival of mouse embryonic stem cells. | Exp Cell Res | 2013 | https://conductscience.org/library/papers/24051329 | PubMed |
| 8 | 30052635 | CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. | PLoS Biol | 2018 | https://conductscience.org/library/papers/30052635 | PubMed |
| 9 | 29228705 | YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. | Oncotarget | 2017 | https://conductscience.org/library/papers/29228705 | PubMed |
| 10 | 35018117 | The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. | Cancer Manag Res | 2022 | https://conductscience.org/library/papers/35018117 | PubMed |
| 11 | 12948524 | The CC chemokine CCL20 and its receptor CCR6. | Cytokine Growth Factor Rev | 2003 | https://conductscience.org/library/papers/12948524 | PubMed |
| 12 | 36813121 | Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer. | Biochem Pharmacol | 2023 | https://conductscience.org/library/papers/36813121 | PubMed |
| 13 | 39880265 | Functional epitope mapping of cell surface glucose-regulated protein 94: A combinatorial approach for therapeutic targeting. | Int J Biol Macromol | 2025 | https://conductscience.org/library/papers/39880265 | PubMed |
| 14 | 39827153 | CK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/39827153 | PubMed |
| 15 | 26735014 | Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. | Nature | 2016 | https://conductscience.org/library/papers/26735014 | PubMed |
| 16 | 22079671 | GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. | Biochim Biophys Acta | 2012 | https://conductscience.org/library/papers/22079671 | PubMed |
| 17 | 30683840 | CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/30683840 | PubMed |
| 18 | 31583500 | Protein kinase CK2 is involved in zinc homeostasis in breast and prostate cancer cells. | Biometals | 2019 | https://conductscience.org/library/papers/31583500 | PubMed |
| 19 | 36499487 | Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36499487 | PubMed |
| 20 | 29807221 | MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells. | Biomed Pharmacother | 2018 | https://conductscience.org/library/papers/29807221 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| COL11A2 | 1302 | PubTator's text mining | https://conductscience.org/library/genes/1302 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42477293
GET https://conductscience.org/api/papers/v1/42477293/references?page=2